| 1. |
- Maksimovic, M., et al.
(författare)
-
First observations and performance of the RPW instrument on board the Solar Orbiter mission
- 2021
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 656
-
Tidskriftsartikel (refereegranskat)abstract
- The Radio and Plasma Waves (RPW) instrument on the ESA Solar Orbiter mission is designed to measure in situ magnetic and electric fields and waves from the continuum up to several hundred kHz. The RPW also observes solar and heliospheric radio emissions up to 16 MHz. It was switched on and its antennae were successfully deployed two days after the launch of Solar Orbiter on February 10, 2020. Since then, the instrument has acquired enough data to make it possible to assess its performance and the electromagnetic disturbances it experiences. In this article, we assess its scientific performance and present the first RPW observations. In particular, we focus on a statistical analysis of the first observations of interplanetary dust by the instrument's Thermal Noise Receiver. We also review the electro-magnetic disturbances that RPW suffers, especially those which potential users of the instrument data should be aware of before starting their research work.
|
|
| 2. |
- Maksimovic, M., et al.
(författare)
-
The Solar Orbiter Radio and Plasma Waves (RPW) instrument
- 2020
-
Ingår i: Astronomy and Astrophysics. - : EDP SCIENCES S A. - 0004-6361 .- 1432-0746. ; 642
-
Tidskriftsartikel (refereegranskat)abstract
- The Radio and Plasma Waves (RPW) instrument on the ESA Solar Orbiter mission is described in this paper. This instrument is designed to measure in-situ magnetic and electric fields and waves from the continuous to a few hundreds of kHz. RPW will also observe solar radio emissions up to 16 MHz. The RPW instrument is of primary importance to the Solar Orbiter mission and science requirements since it is essential to answer three of the four mission overarching science objectives. In addition RPW will exchange on-board data with the other in-situ instruments in order to process algorithms for interplanetary shocks and type III langmuir waves detections.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Nyberg, Joakim, 1978-, et al.
(författare)
-
Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
- 2016
-
Ingår i: CPT. - : Wiley. - 2163-8306. ; 5:4, s. 222-232
-
Tidskriftsartikel (refereegranskat)abstract
- Edoxaban exposure-response relationships from the phase III study evaluating edoxaban for prevention and treatment of venous thromboembolism (VTE) in patients with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE) were assessed by parametric time-to-event analysis. Statistical significant exposure-response relationships were recurrent VTE with hazard ratio (HR) based on average edoxaban concentration at steady state (C-av) (HRCav) 50.98 (i.e., change in the HR with every 1 ng/mL increase of C-av); the composite of recurrent DVT and nonfatal PE with HRC(av)50.99; and the composite of recurrent DVT, nonfatal PE, and all-cause mortality HRC(av)50.98, and all death using maximal edoxaban concentration (C-max) with HR (C-max) 50.99. No statistical significant exposure-response relationships were found for clinically relevant bleeding or major adverse cardiovascular event. Results support the recommendation of once-daily edoxaban 60 mg, and a reduced 30 mg dose in patients with moderate renal impairment, body weight <= 60 kg, or use of P-glycoprotein inhibitors verapamil or quinidine.
|
|
| 8. |
- Baverel, Paul G, et al.
(författare)
-
Predictive performance of internal and external validation procedures
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Purpose: To compare estimates of predictive performance between internal (IV) and external data-splitting (EV) validation procedures. Methods: Datasets of different study size (n=6, 12, 24, 48, 96, 192, or 384 individuals) were simulated from a one compartment, first-order absorption, pharmacokinetic model and both parametric (FOCE), and nonparametric (NONP) parameter estimates were obtained in NONMEM. From these, three different validation procedures (IV, EV, and a population validation (PV)) were undertaken by means of numerical predictive checks (NPCs) to provide estimates of predictive performance, the PV procedure serving as a reference to assess performance of IV and EV. The predictive performance of NONP versus FOCE estimates was further assessed. Results: Estimates of predictive performance for predicting the median of the population distribution had in general significantly lower imprecision for IV than EV, with little bias for both procedures. For small study sizes, n=6-12 (FOCE) or n=6-24 (NONP), the tails of the population distribution were significantly more biased with IV than EV, but similar imprecision was obtained. The predictive performance for FOCE was similar or superior to that of NONP. Conclusions: Data-splitting is inferior to IV when evaluating predictive models to retain sufficient precision both in predictions and in estimates of predictive performance.
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
- Karlsson, Kristin C., et al.
(författare)
-
A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling
- 2009
-
Ingår i: Therapeutic Drug Monitoring. - 0163-4356 .- 1536-3694. ; 31:1, s. 86-94
-
Tidskriftsartikel (refereegranskat)abstract
- Gabapentin is used in analgesic treatment of neuropathic pain, and large interindividual variation has been observed in the pharmacokinetics (PK) of the drug. The aim of this study was to develop a population PK model for gabapentin appropriate for monitoring patients with neuropathic pain and for individualizing their dose regimens. Steady-state serum concentrations of gabapentin, distributed over a dosage interval, were obtained from 16 adult patients. Data were analyzed with an iterative 2-stage Bayesian and a nonparametric adaptive grid algorithm (NPAG) (USC*PACK) and with nonlinear mixed effects modeling (NONMEM). Compartmental population models for gabapentin PK were developed in NPAG and NONMEM using creatinine clearance and body weight as covariates. Bioavailability was included in the models as a function of dose by using a hyperbolic function derived from data previously reported in the literature. The mean population parameter estimates from the final NPAG model predicted individual serum concentrations reasonably well. The models developed in NONMEM provided additional information about the relevance of the various possible covariates and also allowed for further evaluation by simulation from the model. The population PK model may be utilized in the MM-USCPACK monitoring software (MM: multiple model dosage design) for predicting and achieving individually optimized steady-state serum concentrations of gabapentin.
|
|
| 12. |
- Karlsson, Kristin C., et al.
(författare)
-
Modeling subpopulations with the $MIXTURE subroutine in NONMEM : finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making
- 2009
-
Ingår i: AAPS Journal. - : Springer. - 1550-7416. ; 11:1, s. 148-154
-
Tidskriftsartikel (refereegranskat)abstract
- In nonlinear mixed effects modeling using NONMEM, mixture models can be used for multimodal distributions of parameters. The fraction of individuals belonging to each of the subpopulations can be estimated, and the most probable subpopulation for each patient is output (MIXEST(k)). The objective function value (OFV) that is minimized is the sum of the OFVs for each patient (OFV(i)), which in turn is the sum across the k subpopulations (OFV(i,k)). The OFV(i,k) values can be used together with the total probability in the population of belonging to subpopulation k to calculate the individual probability of belonging to the subpopulation (IP(k)). Our objective was to explore the information gained by using IP(k) instead of or in addition to MIXEST(k) in the analysis of mixture models. Two real data sets described previously by mixture models as well as simulations were used to explore the use of IP(k) and the precision of individual parameter values based on IP(k) and MIXEST(k). For both real data-based mixture models, a substantial fraction (11% and 26%) of the patients had IP(k) values not close to 0 or 1 (IP(k) between 0.25 and 0.75). Simulations of eight different scenarios showed that individual parameter estimates based on MIXEST were less precise than those based on IP(k), as the root mean squared error was reduced for IP(k) in all scenarios. A probability estimate such as IP(k) provides more detailed information about each individual than the discrete MIXEST(k). Individual parameter estimates based on IP(k) should be preferable whenever individual parameter estimates are to be used as study output or for simulations.
|
|
| 13. |
- Karlsson, Kristin E, 1975-
(författare)
-
Benefits of Pharmacometric Model-Based Design and Analysis of Clinical Trials
- 2010
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Quantitative pharmacokinetic-pharmacodynamic and disease progression models are the core of the science of pharmacometrics which has been identified as one of the strategies that can make drug development more effective. To adequately develop and utilize these models one needs to carefully consider the nature of the data, choice of appropriate estimation methods, model evaluation strategies, and, most importantly, the intended use of the model. The general aim of this thesis was to investigate how the use of pharmacometric models can improve the design and analysis of clinical trials within drug development. The development of pharmacometric models for clinical assessment scales in stroke and graded severity events, in this thesis, show the benefit of describing data as close to its true nature as possible, as it increases the predictive abilities and allows for mechanistic interpretations of the models. Performance of three estimation methods implemented in the mixed-effects modeling software NONMEM; 1) Laplace, 2) SAEM, and 3) Importance sampling, applied when modeling repeated time-to-event data, was investigated. The two latter methods are to be preferred if less than approximately half of the individuals experience events. In addition, predictive performance of two validation procedures, internal and external validation, was explored, with internal validation being preferred in most cases. Model-based analysis was compared to conventional methods by the use of clinical trial simulations and the power to detect a drug effect was improved with a pharmacometric design and analysis. Throughout this thesis several examples have shown the possibility of significantly reducing sample sizes in clinical trials with a pharmacometric model-based analysis. This approach will reduce time and costs spent in the development of new drug therapies, but foremost reduce the number of healthy volunteers and patients exposed to experimental drugs.
|
|
| 14. |
- Karlsson, Kristin E, et al.
(författare)
-
Comparisons of Analysis Methods for Proof-of-Concept Trials
- 2013
-
Ingår i: CPT. - : Wiley. - 2163-8306. ; 2, s. e23-
-
Tidskriftsartikel (refereegranskat)abstract
- Drug development struggles with high costs and time consuming processes. Hence, a need for new strategies has been accentuated by many stakeholders in drug development. This study proposes the use of pharmacometric models to rationalize drug development. Two simulated examples, within the therapeutic areas of acute stroke and type 2 diabetes, are utilized to compare a pharmacometric model–based analysis to a t-test with respect to study power of proof-of-concept (POC) trials. In all investigated examples and scenarios, the conventional statistical analysis resulted in several fold larger study sizes to achieve 80% power. For a scenario with a parallel design of one placebo group and one active dose arm, the difference between the conventional and pharmacometric approach was 4.3- and 8.4-fold, for the stroke and diabetes example, respectively. Although the model-based power depend on the model assumptions, in these scenarios, the pharmacometric model–based approach was demonstrated to permit drastic streamlining of POC trials.
|
|
| 15. |
- Karlsson, Kristin E., et al.
(författare)
-
Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales
- 2010
-
Ingår i: AAPS Journal. - : Springer Science and Business Media LLC. - 1550-7416. ; 12:4, s. 683-691
-
Tidskriftsartikel (refereegranskat)abstract
- This article demonstrates techniques for describing and predicting disease progression in acute stroke by modeling scores measured using clinical assessment scales, accommodating dropout as an additional source of information. Scores assessed using the National Institutes of Health Stroke Scale and the Barthel Index in acute stroke patients were used to model the time course of disease progression. Simultaneous continuous and probabilistic models for describing the nature and magnitude of score changes were developed, and used to model the trajectory of disease progression using scale scores. The models described the observed data well, and exhibited good simulation properties. Applications include longitudinal analysis of stroke scale data, clinical trial simulation, and prognostic forecasting. Based upon experience in other areas, it is likely that application of this modeling methodology will enable reductions in the number of patients needed to carry out clinical studies of treatments for acute stroke.
|
|
| 16. |
- Karlsson, Kristin E., et al.
(författare)
-
Performance of three estimation methods in repeated time-to-event modeling
- 2011
-
Ingår i: AAPS Journal. - : Springer Science and Business Media LLC. - 1550-7416. ; 13:1, s. 83-91
-
Tidskriftsartikel (refereegranskat)abstract
- It is not uncommon that the outcome measurements, symptoms or side effects, of a clinical trial belong to the family of event type data, e.g., bleeding episodes or emesis events. Event data is often low in information content and the mixed-effects modeling software NONMEM has previously been shown to perform poorly with low information ordered categorical data. The aim of this investigation was to assess the performance of the Laplace method, the stochastic approximation expectation-maximization (SAEM) method, and the importance sampling method when modeling repeated time-to-event data. The Laplace method already existed, whereas the two latter methods have recently become available in NONMEM 7. A stochastic simulation and estimation study was performed to assess the performance of the three estimation methods when applied to a repeated time-to-event model with a constant hazard associated with an exponential interindividual variability. Various conditions were investigated, ranging from rare to frequent events and from low to high interindividual variability. The method performance was assessed by parameter bias and precision. Due to the lack of information content under conditions where very few events were observed, all three methods exhibit parameter bias and imprecision, however most pronounced by the Laplace method. The performance of the SAEM and importance sampling were generally higher than Laplace when the frequency of individuals with events was less than 43%, while at frequencies above that all methods were equal in performance.
|
|
| 17. |
- Karlsson, Kristin E., et al.
(författare)
-
Randomized exposure-controlled trials : Impact of randomization and analysis strategies
- 2007
-
Ingår i: British Journal of Clinical Pharmacology. - : Wiley. - 0306-5251 .- 1365-2125. ; 64:3, s. 266-277
-
Tidskriftsartikel (refereegranskat)abstract
- Aims: In the literature, five potential benefits of randomizing clinical trials on concentration levels, rather than dose, have been proposed: (i) statistical study power will increase; (ii) study power will be less sensitive to high variability in the pharmacokinetics (PK); (iii) the power of establishing an exposure-response relationship will be robust to correlations between PK and pharmacodynamics (PD); (iv) estimates of the exposure-response relationship are likely to be less biased; and (v) studies will provide a better control of exposure in situations with toxicity issues. The main aim of this study was to investigate if these five statements are valid when the trial results are evaluated using a model-based analysis. Methods: Quantitative relationships between drug dose, concentration, biomarker and clinical end-point were defined using pharmacometric models. Three randomization schemes for exposure-controlled trials, dose-controlled (RDCT), concentration-controlled (RCCT) and biomarker-controlled (RBCT), were simulated and analysed according to the models. Results: (i) The RCCT and RBCT had lower statistical power than RDCT in a model-based analysis; (ii) with a model-based analysis the power for an RDCT increased with increasing PK variability; (iii) the statistical power in a model-based analysis was robust to correlations between CL and EC 50 or Emax; (iv) under all conditions the bias was negligible (<3%); and (v) for studies with equal power RCCT could produce either more or fewer adverse events compared with an RDCT. Conclusion: Alternative randomization schemes may not have the proposed advantages if a model-based analysis is employed.
|
|
| 18. |
- Krekels, Elke H. J., et al.
(författare)
-
Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial
- 2016
-
Ingår i: Clinical Pharmacokinetics. - : Springer Science and Business Media LLC. - 0312-5963 .- 1179-1926. ; 55:9, s. 1079-1090
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Edoxaban is a novel factor Xa inhibitor. This study characterizes the population pharmacokinetics of edoxaban in patients with non-valvular atrial fibrillation (NVAF) included in the phase III ENGAGE AF-TIMI 48 study, evaluates covariates for the dose-exposure relationship in this population, and assesses the impact of protocol-specified dose reductions on exposure using simulations.Methods: Model development was performed using NONMEMA (R) and based on sparse data from the ENGAGE AF-TIMI 48 study augmented with dense data from 13 phase I studies to inform and stabilize the model. The influence of body weight (WT), creatinine clearance (CLCR), concomitant P-glycoprotein (P-gp) inhibitors, age, sex, race, and NVAF on pharmacokinetic parameters was evaluated based on statistical significance and clinical relevance.Results: A two-compartment model with first-order elimination and first-order absorption after an absorption lag-time best described the data. Apparent volume and clearance terms increased with increasing WT. Apparent renal clearance increased with increasing CLCR. Apparent non-renal, renal, and inter-compartmental clearance terms differed between phase I volunteers and NVAF patients. Asian patients were found to have increased apparent central volume of distribution, bioavailability, and total apparent clearance. Concomitant P-gp inhibitors increased the bioavailability statistically significantly, but this did not reach clinical relevance.Conclusion: Edoxaban disposition and the variability in this disposition, including influence of covariates, after oral administration were adequately characterized in patients with NVAF. The 50 % dose reduction in patients with low WT (aecurrency sign60 kg), moderate renal impairment (CLCR aecurrency sign50 mL/min), or concomitant P-gp inhibitors led to 30 % lower exposure than in the other patients.
|
|
| 19. |
- Magnusson, Mats O., 1975-
(författare)
-
Pharmacodynamics of Enzyme Induction and its Consequences for Substrate Elimination
- 2007
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Enzyme induction is a process whereby a molecule enhances the expression of enzymes. If the affected enzymes are involved in the elimination of a drug, this may result in a drug interaction. Induction is therefore of major concern during drug development and in clinical practice. The induction process depends on the half-life of the induced enzyme, the pharmacokinetics of the inducing agent, and the relationship between the inducer’s concentration and the induction stimulus. The aim of the conducted research was to investigate these key aspects of enzyme induction and the consequences that induction has for substrate elimination.Successful investigations of the induction process presuppose the existence of appropriate methods for the estimation of the metabolic activity. Enzyme activity measurements can be conducted in tissues with low enzyme content using the analytical method presented here. A model was developed describing the changes in the pharmacokinetics of clomethiazole and its metabolite NLA-715, that are attributable to carbamazepine induction. The consequences of the induction was explained using a mechanistic approach, acknowledging food-induced changes in the blood flow to the liver, and interpreting in vitro generated metabolic information.The time course of the induction process was examined in two investigations. In the first of these, the pharmacokinetics of the autoinducing drug phenobarbital and its effect on several enzymes were described in rats. This was accomplished by integrating the bidirectional interaction between drug and enzymes in a mechanistic manner. In the final investigation, the time course of the increase and cessation in enzyme activity was studied in healthy volunteers treated with carbamazepine. This investigation allowed the half-lives of CYP3A and CYP1A2 to be estimated. The key aspects of the enzyme induction process have been examined using mechanistic induction models. These novel models improve the understanding of the induction process and its consequences for substrate elimination.
|
|
| 20. |
|
|
| 21. |
- Plan, Elodie L., et al.
(författare)
-
Approaches to simultaneous analysis of frequency and severity of symptoms
- 2010
-
Ingår i: Clinical Pharmacology and Therapeutics. - : Springer Science and Business Media LLC. - 0009-9236 .- 1532-6535. ; 88:2, s. 255-259
-
Tidskriftsartikel (refereegranskat)abstract
- Mechanistic models that synthesize pharmacological and (patho) physiological process information provide a rich basis for the characterization of drug action. However, the underlying clinical data are often simplified in a manner that does not allow models to fully elucidate the structure of the drug effect. In this article, we describe data-simplification strategies that are in routine use to describe disease symptoms and compare them with a model developed for handling the true complexities of the data.
|
|
| 22. |
- Plan, Elodie L, et al.
(författare)
-
Transient Lower Esophageal Sphincter Relaxations PKPD Modeling : Count Model and Repeated Time-To-Event Model
- 2011
-
Ingår i: Journal of Pharmacology and Experimental Therapeutics. - : American Society for Pharmacology & Experimental Therapeutics (ASPET). - 0022-3565 .- 1521-0103.
-
Tidskriftsartikel (refereegranskat)abstract
- Transient lower esophageal sphincter relaxation (TLESR) is the major mechanism for gastro-esophageal reflux. Characterization of candidate compounds for reduction of TLESRs are traditionally done through summary exposure and response measures and would benefit from model-based analyses of exposure-TLESR events relationships. PKPD modeling approaches treating TLESR either as count data or as repeated time-to-event (RTTE) data were developed and compared in terms of ability to characterize system and drug characteristics. Vehicle data comprising 294 TLESR events were collected from 9 dogs. Compound (WIN55251-2) data containing 66 TLESR events, as well as plasma concentrations, were obtained from 4 dogs. Each experiment lasted for 45min and was initiated with a meal. Counts in equispaced 5-min intervals and 1-min intervals were modeled based on a Poisson probability distribution model. TLESR events were analyzed with the RTTE model. PK was connected to PD models with a 1-compartment model. Vehicle data were described by a baseline and a surge function; the surge peak was determined around 9.69min by all approaches and its width of 5min (1-min count and RTTE) or 10min (5-min count). TLESRs inhibition by WIN55251-2 was described by an Imax model, with an IC50 of on average 2.39nmol.L-1. Modeling approaches utilizing count or RTTE data linked to a dynamic PKPD representation of exposure is superior to using summary PK and PD measures. Differences in terms of predictions and power to detect a significant drug effect are illustrated with a simulation-based investigation, and a range of diagnostics for such modeling approaches is presented.
|
|
| 23. |
- Szamota-Leandersson, Karolina, et al.
(författare)
-
Adsorption of Cs on InAs(111) surfaces
- 2006
-
Ingår i: Applied Surface Science. - : Elsevier BV. - 0169-4332 .- 1873-5584. ; 252:15, s. 5267-5270
-
Tidskriftsartikel (refereegranskat)abstract
- Caesiated InAs(111)B (1 x 1) and InAs(111)A (2 x 2) surfaces have been studied by photoelectron spectroscopy. On the InAs(111)B a new (root 3 x root 3)R30 degrees reconstruction was observed. During Cs evaporation remarkably small changes are observed in the lone pair states, and no sign of an accumulation layer at the surface can be observed. Instead, the additional charge provided by Cs is rapidly transported towards the bulk. On the InAs(111)A cesium behaves as a typical electropositive alkali metal donator that enhances the already existing accumulation layer.
|
|
| 24. |
- Szamota-Leandersson, Karolina, et al.
(författare)
-
Correlated development of a (2x2) reconstruction and acharge accumulation layer on the InAs(111)-Bi surface
- 2011
-
Ingår i: Surface Science. - : Elsevier BV. - 0039-6028 .- 1879-2758. ; 605:1-2, s. 12-17
-
Tidskriftsartikel (refereegranskat)abstract
- We have studied the formation of a Bi induced (2x2) reconstruction on the InAs(111)Bsurface. In connection to the development of the (2x2) reconstruction, a two dimensionalcharge accumulation layer located in the bottom of the InAs conduction band appears as seenthrough a photoemission structure at the Fermi level. Not well ordered Bi layers do not inducea charge accumulation. The Bi induced reconstruction reduces the polarisation of the pristinesurface and changes the initial charge distribution. InAsBi alloying occurs below the surfacewhere Bi act as charge donor leading to the charge accumulation layer.
|
|
| 25. |
- Szamota-Leandersson, Karolina, et al.
(författare)
-
Electronic structure of bismuth terminated InAs(100)
- 2009
-
Ingår i: Surface Science. - : Elsevier BV. - 0039-6028 .- 1879-2758. ; 603:1, s. 190-196
-
Tidskriftsartikel (refereegranskat)abstract
- Deposition of Bi onto (4 x 2)/c(8 x 2)-InAs(1 0 0) and subsequent annealing results in a (2 x 6) surface reconstruction as seen by low electron energy diffraction. The Bi condensation eliminates the original (4 x 2) Surface reconstruction and creates a new Structure including Bi-dimers. This Surface is metallic and hosts a charge accumulation layer seen through photoemission intensity near the Fermi level. The accumulation layer is located in the bulk region below the surface, but the intensity of the Fermi level structure is strongly dependent oil the Surface order.
|
|
